Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 4Unknown 1Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Breast Neoplasms 414Carcinoma, Non-Small-Cell Lung 287Prostatic Neoplasms 208Neoplasms 204Neoplasm Metastasis 181Melanoma 164Colorectal Neoplasms 159Multiple Myeloma 158Leukemia, Myeloid, Acute 143Lung Neoplasms 132Leukemia 126Lymphoma 118Pancreatic Neoplasms 117Recurrence 111Ovarian Neoplasms 111Leukemia, Lymphocytic, Chronic, B-Cell 110Lymphoma, Non-Hodgkin 105Carcinoma, Renal Cell 104Brain Neoplasms 90Myelodysplastic Syndromes 88Precursor Cell Lymphoblastic Leukemia-Lymphoma 86Glioblastoma 85Lymphoma, Large B-Cell, Diffuse 80Lymphoma, Follicular 79Carcinoma, Hepatocellular 79Head and Neck Neoplasms 77Squamous Cell Carcinoma of Head and Neck 76Urinary Bladder Neoplasms 66Stomach Neoplasms 61Hodgkin Disease 60

Interventions

pazopanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Terminated × Paraganglioma, Extra-Adrenal × Clear all
NCT01340794 2017-09-21

Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma

National Cancer Institute (NCI)

Phase 2 Terminated
7 enrolled 8 charts
CNSEndocrine

Paraganglioma, Paraganglioma, Extra-Adrenal, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡